Estamos no ar no ! Saiba mais

Cryo-Cell International

CCEL

Valor de mercado US$ 35,6 mi

4,42 USD

+0,77

21,1%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

4,47

+0,05

1,13%

1 dia

21,1%

5 dias

-6,95%

1 mês

0,23%

3 meses

27,01%

6 meses

22,1%

No acumulado do ano

28,86%

1 ano

-1,78%

5 anos

-65,17%

10 anos

-61,9%

Sobre: Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.

Funcionários: 76

Saúde Estabelecimentos de assistência médica

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 0%

Neutro 100%

Negativo 0%

Goodyear Tire, Cryo-Cell International and 3 Stocks to Watch Heading Into Monday

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:

Goodyear Tire, Cryo-Cell International and 3 Stocks to Watch Heading Into Monday

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2026 Financial Results

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American, Symbol: CCEL) (the “Company”, “Cryo-Cell”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2026. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2026 were $7.82 million compared to $7.83 million for the third quarter of fiscal 2025. Net Income The Company reported net income of $1.27 mil.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2026 Financial Results

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2026. Financial Results Revenue The revenues for the second quarter of fiscal 2026 were $7.8 million compared to $7.9 million for the second quarter of fiscal 2025, a 2% decrease. The revenues for the second quarter of fiscal 2026 consisted of $7.7.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results

Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American") has accepted the Company's previously submitted plan to regain compliance with continued listing standards. As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Co.

Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American

Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT”) Accreditation for Cord Blood Collection, Banking, and Release for Administration (Related and Unrelated) Donations. Originally accredited in 2014, the Company's latest FACT re-accreditation extends for three more years, with the latest renewal effective through Ap.

Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2026. Financial Results Revenue The revenues for the first quarter of fiscal 2026 were $7.68 million compared to $7.97 million for the first quarter of fiscal 2025. The revenues for the first quarter of fiscal 2026 consisted of $7.64 million i.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results

Cryo-Cell Receives NYSE American Continued Listing Notice

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced that is has received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with certain continued listing standards set forth in the NYSE American Company Guide. Specifically, the Notice indicated that the Company is not in com.

Cryo-Cell Receives NYSE American Continued Listing Notice

Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2025. Financial Results Revenue Consolidated revenues for fiscal 2025 were $31.6 million compared to $32.0 million for fiscal 2024. The revenues for fiscal 2025 consisted of $31.4 million in processing and storage fee revenue, $54,000 in product revenue.

Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2025 Financial Results

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”, “Cryo-Cell”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2025. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2025 were $7.83 million compared to $8.07 million for the third quarter of fiscal 2024, a 3% decrease. Net Income The Company reported net i.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2025 Financial Results

Cryo-Cell International, Inc. Provides Dividend Update

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”, “Cryo-Cell”), the world's first private cord blood bank to separate and store stem cells in 1992, announced that the Company will not declare a quarterly cash dividend for the third quarter of fiscal 2025. This decision reflects lower-than-expected profitability. Cryo-Cell may or may not reinstate a dividend in future periods, and any future decisions regarding dividend declarations will be b.

Cryo-Cell International, Inc. Provides Dividend Update

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™